Ernexa Therapeutics (NASDAQ:ERNA) Shares Down 15.4% – Here’s What Happened

Ernexa Therapeutics Inc. (NASDAQ:ERNA) shares were down 15.4% during trading on Monday . The company traded as low as $5.33 and last traded at $5.43. Approximately 248,372 shares were traded during trading, a decline of 82% from the average session volume of 1,359,927 shares. The stock had previously closed at $6.42.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a research report on Monday, May 11th. Brookline Capital Markets began coverage on Ernexa Therapeutics in a research report on Thursday, May 7th. They set a “buy” rating and a $30.00 price target on the stock. Wall Street Zen upgraded Ernexa Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $30.00.

Ernexa Therapeutics Stock Performance

The company has a market capitalization of $6.35 million, a PE ratio of -0.21 and a beta of 2.50. The company’s 50-day simple moving average is $8.05 and its 200-day simple moving average is $11.37.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its earnings results on Monday, May 11th. The company reported ($6.95) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00). Analysts expect that Ernexa Therapeutics Inc. will post -18.02 EPS for the current year.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent quarter. Institutional investors own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.